The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma

Lenalidomide is an integral, yet evolving, part of current treatment pathways for both transplant-eligible and transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). It is approved in combination with dexamethasone as first-line therapy for transplant-ineligible patients with N...

Descripción completa

Detalles Bibliográficos
Autores principales: Merz, Maximilian, Dechow, Tobias, Scheytt, Mithun, Schmidt, Christian, Hackanson, Bjoern, Knop, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340649/
https://www.ncbi.nlm.nih.gov/pubmed/32296915
http://dx.doi.org/10.1007/s00277-020-04023-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340649/
https://www.ncbi.nlm.nih.gov/pubmed/32296915
http://dx.doi.org/10.1007/s00277-020-04023-4

Ejemplares similares